AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Affinity photo tethering 20199/21/2023 The Scripps Research Institute, Jupiter, FL, USAĬhristoph Rader studied biochemistry in Germany and Switzerland where he received his PhD from the University of Zurich in 1995. In 2010, she was the founding co-organizer of the Antibody Biology and Engineering Gordon Research Conference.ĭepartment of Immunology and Microbiology This involves a combination of antibody/protein engineering, fluorescence microscopy and in vivo studies in mouse models of disease. Professor Ward’s research is directed towards taking a highly interdisciplinary approach to generate effective therapeutics for autoimmunity and cancer. She has recently been appointed as the Director of Translational Immunology and Professor of Molecular Immunology at the Centre for Cancer Immunology at the University of Southampton. Since 2014, she has been a Professor at Texas A&M University Health Science Center. From 2002-2014, she was a Professor in the Department of Immunology at the same institution and in 2004 was appointed to the Paul and Betty Meek-FINA Professorship in Molecular Immunology. In 1990 she joined the University of Texas Southwestern Medical Center, Dallas, as an Assistant Professor. She held the Stanley Elmore Senior Research Fellowship at Sidney Sussex College from 1988-1990 whilst carrying out research in Sir Greg Winter’s laboratory at the MRC Laboratory of Molecular Biology in Cambridge. research in the Department of Biochemistry, Cambridge University, under the mentorship of Professor David Ellar. The Centre for Cancer Immunology, University of Southampton, UK He is an elected member of the US National Academy of Science, American Association of Arts and Science, and the National Academy of Inventors. His team was integral to several protein products including Somavert for acromegaly, Avastin for cancer, and engineered proteases sold by Pfizer, Genentech and Genencor, respectively. These lead to important new insights into protease mechanisms, growth factor signaling, hot-spots in protein-protein interfaces, role of caspases in biology, and more recently determining how cell surfaces change in health and disease. Jim pioneered the engineering of proteins, antibodies, and small molecules that target catalytic, allosteric, and protein-protein interaction sites and technologies including protein phage display, alanine-scanning, engineered proteases for improved hydrolysis, bioconjugations, N-terminomics, disulfide “tethering” (a novel site-directed fragment based approach for drug discovery), and more recently an industrialized recombinant antibody production pipeline for the proteome. He has established successful spin out companies including: Cambridge Antibody Technology (acquired by AstraZeneca), Domantis (acquired by GlaxoSmithKline) and Bicycle Therapeutics.ĭepartment of Pharmaceutical Chemistry, UCSF More recently he has focussed on the development of bicyclic peptides as small antibody mimics. He pioneered techniques to make humanised and human therapeutic antibodies, leading to antibody therapies for cancer and diseases such as rheumatoid arthritis and multiple sclerosis. In his early research Greg was interested in the idea that all antibodies have the same basic structure, with only small changes making them specific for one target. His main research focus is genetic and protein engineering. He has also been awarded numerous prizes and medals and received a Knighthood for services to Molecular Biology in 2004. He was elected a member of the European Molecular Biology Organisation in 1987, a Fellow of the Royal Society in 1990, as well as a Fellow or Honorary Fellow of other professional organizations. Greg Winter is a Fellow of Trinity College, Cambridge and has been Master of Trinity since 2012.
0 Comments
Read More
Leave a Reply. |